Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in Cancer Retrieve available abstracts of 54 articles: HTML format Text format

Single Articles

December 2011
1. HYMAN DM , Zhou Q, Iasonos A, Grisham RN, et al
   Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
   Cancer. 2011 Dec 2. doi: 10.1002/cncr.26655.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. TRIVERS KF , Baldwin LM, Miller JW, Matthews B, et al
   Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
   Cancer. 2011;117:5334-43.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
3. ROSE PG
   Which is the best foot to put forward in recurrent ovarian cancer?
   Cancer. 2011 Nov 9. doi: 10.1002/cncr.26615.
   PubMed     Text format     Related articles   
   
   
   
   
4. SECORD AA , Berchuck A, Higgins RV, Nycum LR, et al
   A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
   Cancer. 2011 Nov 9. doi: 10.1002/cncr.26610.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
5. HENSLEY ML , Kravetz S, Jia X, Iasonos A, et al
   Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study.
   Cancer. 2011 Sep 20. doi: 10.1002/cncr.26569.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   August 2011
6. KIM G , Davidson B, Henning R, Wang J, et al
   Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.
   Cancer. 2011 Aug 25. doi: 10.1002/cncr.26449.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. MCGONIGLE KF , Muntz HG, Vuky J, Paley PJ, et al
   Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a Phase 2 Study.
   Cancer. 2011;117:3731-40.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. PRINTZ C
   ASCO highlights new findings on cancer screening discoveries connected to ovarian, cervical, and prostate cancers.
   Cancer. 2011;117:3627-8.
   PubMed     Text format     Related articles   
   
   
   
   July 2011
9. FLEMING ND , Agadjanian H, Nassanian H, Miller CW, et al
   Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
   Cancer. 2011 Jul 12. doi: 10.1002/cncr.26329.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   June 2011
10. MOORE LE , Pfeiffer RM, Zhang Z, Lu KH, et al
    Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial.
    Cancer. 2011 Jun 29. doi: 10.1002/cncr.26241.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. CASAGRANDE F , Cocco E, Bellone S, Richter CE, et al
    Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin.
    Cancer. 2011 Jun 20. doi: 10.1002/cncr.26215.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. WESTIN SN , Sun CC, Lu KH, Schmeler KM, et al
    Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
    Cancer. 2011;117:2659-67.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
13. HAVRILESKY LJ , Pokrzywinski R, Revicki D, Higgins RV, et al
    Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2011 May 19. doi: 10.1002/cncr.26199.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. CHOI CH , Lee YY, Song TJ, Park HS, et al
    Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
    Cancer. 2011;117:2104-11.
    PubMed     Text format     Related articles   
    
    
    
    
15. CHENG L , Roth LM, Zhang S, Wang M, et al
    KIT gene mutation and amplification in dysgerminoma of the ovary.
    Cancer. 2011;117:2096-103.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
16. FU S , Hu W, Iyer R, Kavanagh JJ, et al
    Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
    Cancer. 2011;117:1661-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. BELL JG
    Early detection of ovarian cancer: If only we had a "Pap smear" for this disease.
    Cancer. 2011 Apr 4. doi: 10.1002/cncr.26025.
    PubMed     Text format     Related articles   
    
    
    
    March 2011
18. GOFF BA , Matthews B, Andrilla CH, Miller JW, et al
    How are symptoms of ovarian cancer managed?: A Study of Primary Care Physicians.
    Cancer. 2011 Mar 16. doi: 10.1002/cncr.26035.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. CHEN MY , Liao WS, Lu Z, Bornmann WG, et al
    Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Cancer. 2011 Mar 16. doi: 10.1002/cncr.26073.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. CANTRELL LA , Westin SN, Van Le L
    The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.
    Cancer. 2011;117:1220-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. HEMMINKI K , Sundquist J, Brandt A
    Incidence and mortality in epithelial ovarian cancer by family history of any cancer.
    Cancer. 2011 Mar 1. doi: 10.1002/cncr.26016.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
22. SCHLUMBRECHT MP , Sun CC, Wong KN, Broaddus RR, et al
    Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma.
    Cancer. 2011 Feb 11. doi: 10.1002/cncr.25929.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. HAVRILESKY LJ , Sanders GD, Kulasingam S, Chino JP, et al
    Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: Implications for potential mortality reduction.
    Cancer. 2011;117:545-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. HARTGE P
    Reducing ovarian cancer death rates through screening.
    Cancer. 2011;117:449-50.
    PubMed     Text format     Related articles   
    
    
    
    
25. GOODMAN A
    Measuring success in ovarian cancer risk reducing strategies.
    Cancer. 2011 Feb 1. doi: 10.1002/cncr.25946.
    PubMed     Text format     Related articles   
    
    
    
    December 2010
26. HAVRILESKY LJ , Sanders GD, Kulasingam S, Chino JP, et al
    Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. HARTGE P
    Reducing ovarian cancer death rates through screening.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    November 2010
28. CHOI CH , Lee YY, Song TJ, Park HS, et al
    Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. CRUM CP , Xian W
    Bringing the p53 signature into focus.
    Cancer. 2010;116:5119-21.
    PubMed     Text format     Related articles   
    
    
    
    
30. FU S , Hu W, Iyer R, Kavanagh JJ, et al
    Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. CANTRELL LA , Westin SN, Van Le L
    The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not effect progression-free or overall survival.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
32. TAN L , Kwok RP, Shukla A, Kshirsagar M, et al
    Trichostatin a restores apaf-1 function in chemoresistant ovarian cancer cells.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. MARKMAN M
    The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
34. BOYD LR , Novetsky AP, Curtin JP
    Ovarian cancer care for the underserved: Are surgical patterns of care different in a public hospital setting?
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
35. ZAINO RJ , Brady MF, Lele SM, Michael H, et al
    Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group Study.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. SOSLOW RA
    Mucinous ovarian carcinoma: Slippery business.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
37. ALI-FEHMI R , Semaan A, Sethi S, Arabi H, et al
    Molecular typing of epithelial ovarian carcinomas using inflammatory markers.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
38. HESS LM , Rong N, Monahan PO, Gupta P, et al
    Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. NORQUIST BM , Garcia RL, Allison KH, Jokinen CH, et al
    The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. LE XF , Mao W, Lu Z, Carter BZ, et al
    Dasatinib induces autophagic cell death in human ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. ANNUNZIATA CM , Stavnes HT, Kleinberg L, Berner A, et al
    Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.
    Cancer. 2010;116:3276-84.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. POYNTER JN , Amatruda JF, Ross JA
    Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
43. FAIRFIELD KM , Lucas FL, Earle CC, Small L, et al
    Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. BAST RC JR
    CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
    Cancer. 2010;116:2850-3.
    PubMed     Text format     Related articles   
    
    
    
    
45. GOLDMAN PA
    CA 125: Value or addiction?
    Cancer. 2010;116:2854-5.
    PubMed     Text format     Related articles   
    
    
    
    
46. WEINRIB AZ , Sephton SE, Degeest K, Penedo F, et al
    Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. FANG F , Balch C, Schilder J, Breen T, et al
    A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
48. NAKAYAMA N , Nakayama K, Shamima Y, Ishikawa M, et al
    Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
49. KAMAT AA , Baldwin M, Urbauer D, Dang D, et al
    Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
50. GERSHENSON DM
    The heterogeneity of epithelial ovarian cancer: getting it right.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
51. BAMIAS A , Psaltopoulou T, Sotiropoulou M, Haidopoulos D, et al
    Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. SAROSY GA , Hussain MM, Seiden MV, Fuller AF, et al
    Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2009
53. BIGORIE V , Morice P, Duvillard P, Antoine M, et al
    Ovarian metastases from breast cancer: report of 29 cases.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. COCCO E , Bellone S, El-Sahwi K, Cargnelutti M, et al
    Serum amyloid A: a novel biomarker for endometrial cancer.
    Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: